<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="7409942S0025-5564(20)30105-X doi: 10.1016/j.mbs.2020.108438108438 : Article Modeling the viral dynamics of" exact="SARS-CoV-2 infection" post="WangSunpengaPanYangbcdWangQuanyibcMiaoHongyueBrownAshley N.fRongLibingâ�Ž[a], [b], [c], [d], [e], [f], [g], â�ŽCorresponding"/>
 <result pre="as long as the COVID-19 resource centre remains active. Abstract" exact="Coronavirus disease 2019" post="(COVID-19), an infectious disease caused by the infection of"/>
 <result pre="and causing the global coronavirus pandemic. The viral dynamics of" exact="SARS-CoV-2 infection" post="have not been quantitatively investigated. In this paper, we"/>
 <result pre="we use mathematical models to study the pathogenic features of" exact="SARS-CoV-2 infection" post="by examining the interaction between the virus, cells and"/>
 <result pre="and immune responses. Models are fit to the data of" exact="SARS-CoV-2 infection" post="in patients and non-human primates. Data fitting and numerical"/>
 <result pre="Data fitting and numerical simulation show that viral dynamics of" exact="SARS-CoV-2 infection" post="have a few distinct stages. In the initial stage,"/>
 <result pre="also evaluate the effect of several potential therapeutic interventions for" exact="SARS-CoV-2 infection." post="Model simulation shows that anti-inflammatory treatments or antiviral drugs"/>
 <result pre="strategies against COVID-19. Highlights â€¢Mathematical models are developed to study" exact="SARS-CoV-2 infection." post="â€¢Models are fit to viral load data of patients"/>
 <result pre="load data of patients and non-human primates. â€¢Viral dynamics of" exact="SARS-CoV-2 infection" post="has a few distinct stages. â€¢Model explains viral rebound"/>
 <result pre="2 (SARS-CoV-2) by the World Health OrganizationÂ [10]. Since then," exact="SARS-CoV-2 infection" post="has been detected in about 190 countries and caused"/>
 <result pre="highly resembles the severe acute respiratory syndrome (SARS-CoV) and the" exact="Middle East respiratory syndrome" post="(MERS-CoV), both classified as beta coronaviruses identified in batsÂ"/>
 <result pre="and transmissibility. Currently, there are no approved antiviral drugs for" exact="SARS-CoV-2 infection." post="Many patients were given symptomatic management such as empirical"/>
 <result pre="[46], [47], [48], [49]. However, the within-host viral dynamics of" exact="SARS-CoV-2 infection" post="have not been quantitatively investigated. Here we use mathematical"/>
 <result pre="we use mathematical models to study the pathogenic characteristics of" exact="SARS-CoV-2 infection" post="by examining the interaction between viral replication and the"/>
 <result pre="These findings may provide new insights into the pathogenesis of" exact="SARS-CoV-2 infection" post="and development of new treatment strategies. 2 Methods 2.1"/>
 <result pre="models, with increasing complexity, to study the viral dynamics of" exact="SARS-CoV-2 infection." post="The first is a very basic model, which only"/>
 <result pre="the third one includes a secondary target cell population of" exact="SARS-CoV-2 infection." post="The basic model is given by the following equations."/>
 <result pre="= p I âˆ’ c V The exact target of" exact="SARS-CoV-2 infection" post="is not fully clear. Based on the findings from"/>
 <result pre="cell. The virus is cleared at a constant rate c." exact="SARS-CoV-2 infection" post="can lead to the diffuse alveolar damage (DAD)Â [60]."/>
 <result pre="the R programming language. 3 Results 3.1 Viral dynamics of" exact="SARS-CoV-2 infection" post="We fit each of the three models Eqs. ((1)â€&quot;(3))"/>
 <result pre="three models Eqs. ((1)â€&quot;(3)) to the viral load data of" exact="SARS-CoV-2 infection" post="in patients from Germany and ChinaÂ [14], [51]. The"/>
 <result pre="simulations of model (3) show that the viral dynamics of" exact="SARS-CoV-2 infection" post="can exhibit a few distinct phases (Fig.Â 5A). During"/>
 <result pre="treat HIV-1 infectionÂ [87], while remdesivir was developed to treat" exact="Ebola" post="and Marburg virus infection, acting as an analog of"/>
 <result pre="novel coronavirus infection. The severe acute respiratory syndrome induced by" exact="SARS-CoV-2 infection" post="is characterized by over-exuberant inflammatory response. Baricitinib, fedratinib and"/>
 <result pre="the secondary target of infection. 4 Discussion Within-host dynamics of" exact="SARS-CoV-2 infection" post="have not been quantitatively investigated. We developed mathematical models"/>
 <result pre="countries. Our study provides explanations to several pathogenic features of" exact="SARS-CoV-2 infection." post="Firstly, SARS-CoV-2â€™s very high transmission capacity is likely to"/>
 <result pre="the model shows that the current best possible control of" exact="SARS-CoV-2 infection" post="might be the adaptive immune response of the infected"/>
 <result pre="results may improve our understanding of the pathogenic features of" exact="SARS-CoV-2 infection." post="Comparison of the prediction by the three models and"/>
 <result pre="the three models and the viral load data suggests that" exact="SARS-CoV-2 infection" post="might have a secondary target. Without the second target"/>
 <result pre="with the data in many patients. The secondary target of" exact="SARS-CoV-2 infection" post="might be lymphocytes. Lymphocytopenia is a predominant feature of"/>
 <result pre="acid truncation in its ORF6Â [53]. These alterations might make" exact="SARS-CoV-2 infection" post="more sensitive to IFN. IFN was also administrated with"/>
 <result pre="using IFN with and without other antiviral drugs to treat" exact="SARS-CoV-2 infection" post="in humans. Table 2 Best fits of model (3)"/>
 <result pre="with 2019 novel coronavirus in Wuhan, ChinaLancet39510223202049750610.1016/S0140-6736(20)30183-531986264 4GuanW.-J.NiZ.-Y.HuY.LiangW.-H.OuC.-Q.HeJ.-X.Clinical characteristics of" exact="Coronavirus disease 2019" post="in ChinaNew Engl. J. Med.202010.1056/NEJMoa2002032 5ZhuN.ZhangD.WangW.LiX.YangB.SongJ.A Novel Coronavirus from"/>
 <result pre="coronavirus-EMCNature4957440201325125410.1038/nature1200523486063 27ScobeyT.YountB.L.SimsA.C.DonaldsonE.F.AgnihothramS.S.MenacheryV.D.Reverse genetics with a full-length infectious cDNA of the" exact="Middle East respiratory syndrome" post="coronavirusProc. Natl. Acad. Sci. USA110402013161571616210.1073/pnas.131154211024043791 28RuanQ.YangK.WangW.JiangL.SongJ.Clinical predictors of mortality"/>
 <result pre="perspectives on immune responsesCell Death Differ.202010.1038/s41418-020-0530-3 38PhuaJ.WengL.LingL.EgiM.LimC.M.DivatiaJ.V.Intensive care management of" exact="coronavirus disease 2019" post="(COVID-19): challenges and recommendationsLancet Respir. Med.202010.1016/s2213-2600(20)30161-2 39ThevarajanI.NguyenT.H.O.KoutsakosM.DruceJ.CalyL.SandtC.E.van.de.Breadth of concomitant"/>
 <result pre="of a novel coronavirusInfect. Dis. Poverty9120202410.1186/s40249-020-00640-332111262 50KimJ.Y.KoJ.H.KimY.KimY.J.KimJ.M.ChungY.S.Viral load kinetics of" exact="SARS-CoV-2 infection" post="in first two patients in KoreaJ. Korean Med. Sci.357202010.3346/jkms.2020.35.e86"/>
 <result pre="cell biology perspectiveEur. Respir. J.5542020200060710.1183/13993003.00607-2020 64MizumotoK.KagayaK.ZarebskiA.ChowellG.Estimating the asymptomatic proportion of" exact="coronavirus disease 2019" post="(COVID-19) cases on board the Diamond Princess cruise ship,"/>
 <result pre="gut enterocytesScience202010.1126/science.abc1669eabc1669 92ChannappanavarR.FehrA.R.ZhengJ.Wohlford-LenaneC.AbrahanteJ.E.MackM.IFN-I Response timing relative to virus replication determines" exact="MERS coronavirus" post="infection outcomesJ. Clin. Invest.130920193625363910.1172/jci126363 93ToturaA.L.BaricR.S.SARS Coronavirus pathogenesis: host innate"/>
</results>
